Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry
Open Access
- 23 December 2022
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 239 (2) , 283-286
Abstract
Key Message. HS patients on biologics have similar COVID-19 outcomes to those on nonbiologic therapyKeywords
This publication has 3 references indexed in Scilit:
- Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 PandemicJournal of Cutaneous Medicine and Surgery, 2021
- Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based studyJournal of Allergy and Clinical Immunology, 2021
- Race-Specific Prevalence of Hidradenitis SuppurativaJournal of Cutaneous Medicine and Surgery, 2020